Stockscreener 앱 받기
60.26
6.75%
-4.67
전일 마감가:
$64.93
열려 있는:
$62.4
하루 거래량:
449.21K
Relative Volume:
0.47
시가총액:
$1.14B
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-41.27
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
-3.24%
1개월 성능:
-0.01%
6개월 성능:
+7,951%
1년 성능:
+4,822%
1일 변동 폭
$57.33
$63.99
1주일 범위
$57.33
$66.92
52주 변동 폭
$0.432
$66.92
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
60.17 | 1.23B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.12 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
828.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Why Nektar Therapeutics stock remains on buy listsWeekly Risk Summary & Fast Exit/Entry Strategy Plans - newser.com
Published on: 2025-11-03 04:48:43 - newser.com
Why Nektar Therapeutics stock remains undervaluedJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Why retail investors pile into Nektar Therapeutics stockInsider Selling & Real-Time Price Movement Reports - newser.com
Using economic indicators to assess Nektar Therapeutics potential2025 Year in Review & Daily Momentum Trading Reports - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Moody Aldrich Partners LLC Invests $1.17 Million in Nektar Therapeutics $NKTR - MarketBeat
Will Nektar Therapeutics continue its uptrend2025 Analyst Calls & AI Driven Price Predictions - newser.com
Nektar Therapeutics (NKTR): Valuation Reset as REZOLVE-AD Phase 2b Data and Analyst Optimism Drive Investor Interest - simplywall.st
Is Nektar Therapeutics (ITH0) stock undervalued at current priceQuarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Is Nektar Therapeutics trending in predictive chart models2025 Valuation Update & Community Supported Trade Ideas - newser.com
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 1-Year HighShould You Buy? - MarketBeat
Is Nektar Therapeutics (ITH0) stock a top dividend aristocrat candidateJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
Is Nektar Therapeutics stock a good choice for value investorsJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - newser.com
Nektar Therapeutics stock hits 52-week high at 65.97 USD By Investing.com - Investing.com Australia
Can Nektar Therapeutics (ITH0) stock sustain free cash flowQuarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
Nektar Therapeutics (NKTR) Is Up 8.0% After Late-Breaking Phase 2b Rezpegaldesleukin Data Announcement - Sahm
What margin trends mean for Nektar Therapeutics stockTrade Entry Summary & Free Daily Entry Point Trade Alerts - newser.com
Nektar Therapeutics stock hits 52-week high at 65.97 USD - Investing.com
Best data tools to analyze Nektar Therapeutics stock2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Nektar Therapeutics (NKTR): Taking a Fresh Look at Valuation After Recent Share Price Rebound - Yahoo Finance
Can volume confirm reversal in Nektar TherapeuticsJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Pattern recognition hints at Nektar Therapeutics upsideRecession Risk & Real-Time Market Trend Scan - newser.com
Nektar (NASDAQ: NKTR) to Webcast Jefferies London Event Nov. 20 with 30-day Replay - Stock Titan
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - sharewise.com
Nektar Therapeutics $NKTR Holdings Trimmed by Deuterium Capital Management LLC - MarketBeat
Can Nektar Therapeutics stock resist market sell offsJuly 2025 Movers & Weekly High Return Opportunities - newser.com
Nektar Therapeutics (NKTR) to Release Earnings on Thursday - MarketBeat
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
0.74%
자본화:
|
볼륨(24시간):